We therefore measured plasma PGRN and interleukin-6 (IL-6) in patients with FTLD, Alzheimer's disease (AD), and healthy (spouse) control subjects to ascertain whether levels of these have potential to discriminate patients with FTLD from other neurodegenerative disorders (AD) and healthy individuals, and also whether they can differentiate between clinical, neurohistologic, and genetic subtypes of FTLD. Here, IL6 is linked to Alzheimer disease.